Helus Pharma Appoints Dr. Robert Langer and Dr. Stephen Brannan to Scientific Advisory Board

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., has bolstered its scientific advisory board with the appointments of Dr. Robert Langer and Dr. Stephen Brannan. Dr. Langer, a renowned figure in biotechnology and drug delivery, and Dr. Brannan, an expert in central nervous system clinical development, bring decades of experience to guide the company's pipeline of novel serotonergic agonists (NSAs). These synthetic molecules are designed to activate serotonin pathways believed to promote neuroplasticity, targeting major depressive disorder and generalized anxiety disorder.

Helus Pharma is advancing two key programs: HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. The company aims to address the large unmet need for mental health treatments by developing drugs that provide durable improvements. With a focus on evidence-based development, Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland.

This news was disseminated by BioMedWire, a specialized communications platform covering biotechnology and life sciences. The full press release is available at https://ibn.fm/CyjTq. For more information on Helus Pharma, visit www.helus.com or follow the team on social media. Investors can stay updated via the company's newsroom at https://ibn.fm/HELP.